Side-by-side · Research reference

DSIPvsMK-677

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticDraft8/36 cited

BPhase 2Reviewed13/45 cited

DSIP

Sleep modulator · Anti-stress

100–200 mcgPer doseSchneider 1986

HumanMechanisticSchneider 1986

HoursHalf-life (est)

SQ · Pre-sleep · Daily during cycle

MK-677

Oral GHS · Ibutamoren

10–25 mgDaily dose (oral)Nass 2008

Phase 2Evidence levelMurphy 1998 Nass 2008

~24 hrHalf-lifeNass 2008

Oral capsule · 1×/day

01Mechanism of Action

Parameter

DSIP

MK-677

Primary target

Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986

Ghrelin receptor (GHS-R1a)Murphy 1998

Pathway

Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986

GHS-R1a → Gαq → Ca²⁺ → sustained GH pulses across 24 hrNass 2008

Downstream effect

Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986

Sustained GH + IGF-1 elevation; appetite stimulation; lean mass preservationNass 2008

Feedback intact?

—

Pulsatile pattern preserved despite long half-lifeMurphy 1998

Origin

Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986

Non-peptide spiroindane-piperidine small molecule designed at MerckMurphy 1998

Antibody development

—

02Dosage Protocols

Parameter

DSIP

MK-677

Standard dose

100–200 mcg SQ pre-sleepSchneider 1986

10–25 mg / day oralNass 2008

25 mg used in Nass 2008 elderly trial; 10–15 mg common community dose.

Frequency

Once daily, pre-sleep

Once daily, oral

Lower / starter dose

50 mcg pre-sleep

5 mg / day

Evidence basis

Human-mechanistic + early clinicalSchneider 1986

Phase 2 trials (Nass 2008, Murphy 1998)Nass 2008 Murphy 1998

Duration

8–12 weeks per cycle

8–16 weeks per cycle (off-cycle to reset receptor sensitivity)

Reconstitution

Bacteriostatic water

Oral, no reconstitution

Timing

30–60 min pre-sleep

Pre-sleep preferred for natural GH pulse alignment

Half-life

Short plasma; CNS effects last hours

~24 hrNass 2008

Once-daily dosing covers 24 hours.

04Side Effects & Safety

Parameter

DSIP

MK-677

Injection site reaction

Mild irritation

—

Drowsiness

Expected effect (intentional)

Common, especially during initial weeks

Vivid dreams

Anecdotally reported

—

Long-term safety

Limited modern RCT data

—

Pregnancy / OB

Avoid

Increased appetite

—

Strong appetite increase via ghrelin agonism

Water retention

—

Mild edema, paresthesias

Glucose tolerance

—

↑ HbA1c +0.3–0.5% in 2-yr elderly trialNass 2008

IGF-1 elevation

—

+50–100% sustainedNass 2008

Cancer risk

—

Contraindicated in active malignancy (GH/IGF-1 axis)

Cardiovascular

—

No clear adverse signal in trials; congestive heart failure caution

Absolute Contraindications

DSIP

·Pregnancy / breastfeeding
·Concurrent CNS-depressant therapy without supervision

MK-677

·Active malignancy
·Pregnancy / breastfeeding
·Disrupted hypothalamic-pituitary axis
·Congestive heart failure (caution)

Relative Contraindications

DSIP

·Severe sleep apnoea (untreated)
·Concurrent benzodiazepine / opioid use

MK-677

·Untreated diabetes
·Pre-diabetes
·Severe insulin resistance

05Administration Protocol

Parameter

DSIP

MK-677

1. Reconstitution

Add 1–2 mL bacteriostatic water to vial.

Capsule or oral solution. No injection.

2. Injection site

SQ — abdomen. Rotate sites.

Oral. Take with or without food.

3. Timing

30–60 min pre-sleep.

Pre-sleep preferred — aligns with natural GH pulse.

4. Storage

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

Capsule: room temp ≤25 °C, dry place.

5. Needle

29–31G insulin syringe.

Monitor HbA1c every 8–12 weeks during chronic use.